secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-06-22T20:05:46+00:00
Accession:  0001628280-26-044618
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene shareholders approve doubling authorized shares to 800M; files $135M ATM offering
--------------------------------------------------------------------------------

- Stockholders approved increase of authorized common shares from 400M to 800M, effective June 18, 2026.
- Advisory 'say-on-pay' vote approved; board adopts annual frequency for future advisory votes.
- Company filed prospectus supplement for up to $135M in common stock sales via ATM with TD Securities.
- All three Class II director nominees (Messemer, Sato, Witte) re-elected with strong support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026044618/0001628280-26-044618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026044618/allo-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-044618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer